Skip to main content

Table 1 Baseline socio-demographic and clinical characteristics of patients on ART at JUTH, Ethiopia 2015

From: Reasons and predictors for antiretroviral therapy change among HIV-infected adults at South West Ethiopia

Baseline characteristics N (%)
Age (years), [interquartile range (IQR)] 30 (26–38)
Sex
 Female 963 (62.8)
 Male 570 (37.2)
Marital status
 In relationship 733 (47.8)
 Not in relationship 798 (52.0)
 Missing values 2
Educational status
 < primary level education 835 (54.5)
 ≥ primary level education 698 (45.5)
Functional status
 Working 1058 (69.0)
 Ambulatory 394 (25.7)
 Bedridden 63 (4.1)
 Missing values 18 (1.2)
Initial CD4
Median (IQR) in cells/mm3 144 (IQR 79–210)
  ≤ 200 1102 (71.8)
  > 200 429 (28)
 Missing values 2
WHO clinical stages
 Stage I 290 (18.9)
 Stage II 436 (28.4)
 Stage III 648 (42.3)
 Stage IV 159 (10.4)
Past opportunistic infections
 Yes 1183 (77.2)
 No 342 (22.3)
 Missing values 8
TB status
 Negative 1207 (78.7)
 Positive 281 (18.3)
 Missing values 45 (2.9)
NNRTIs
 NVP-based 1056 (68.9)
 EFV-based 477 (31.1)
NRTIs
 D4T-based 942 (61.4)
 TDF-based 338 (22.0)
 ZDV-based 253 (16.5)
  1. WHO clinical stage I indicates asymptomatic and persistent generalized lymphadenopathy; WHO clinical Stage 3 was defined if one of the following is present: weight loss of > 10% body weight, chronic diarrhea for > 1 month, fever for > 1 month, oral candidiasis, or pulmonary Tb within the previous year, or severe bacterial infections; WHO clinical Stage 4 was defined if one of the following is present in an HIV diagnosed patient: HIV wasting syndrome, (Pneumocystcarini pneumonia)PCP, toxoplasmosis of the brain, cryptosporidiosis with diarrhea for > 1 month, cytomegalovirus disease, herpes simplex virus infection, progressive multifocal leukoencephalopathy, candidiasis, extra-pulmonary Tb, lymphoma, kaposi’s sarcoma
  2. NNRTIs non-nucleoside reverse transcriptase inhibitors, NRTIs nucleoside reverse transcriptase inhibitors, NVP Nevirapine, EFV Efavirenz, D4T Stavudine, TDF Tenofovir, ZDV Zidovudine